{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Objective response is defined as achieving partial response or better on therapy based on the Consensus Panel Recommendations from the 2nd and 3rd International Workshop on WM \\[Weber et al, 2003; Kimby et al, 2005\\]. Complete Response (CR): Complete disappearance of serum monoclonal (SM) Immunoglobulin (Ig) E (IgE), measured centrally; resolution of adenopathy/organomegaly upon physical exam and computerized tomography (CT) scan; lymph nodes =\\<1.5 centimeters; absence of malignant cell by bone marrow histologic examination. Partial Response (PR): a \\>=50% reduction from baseline in the SM IgM concentration. Minor Response (MR): \\>=25%, but a \\<50% reduction of SM IgM from baseline.","groups":[{"description":"Simvastatin at 20 mg daily for the first week, then dose escalated weekly by 20 mg a day to a maximum of 80 mg daily by week 4. Patients were maintained on therapy until progression or up to 2 years.","id":"OG000","title":"Simvastatin"}],"paramType":"NUMBER","populationDescription":"The analysis dataset is comprised of all evaluable patients. One patient was lost to follow-up within 3 weeks of enrollment and was unevaluable.","reportingStatus":"POSTED","timeFrame":"Assessed at month 1 and 3 and thereafter every 3 months while on therapy. Median duration on treatment was 6 months (range 1-24 months).","title":"Objective Response Rate","type":"PRIMARY","unitOfMeasure":"proportion of patients"}